Explore the key elements of an effective price policy and the tools available to streamline pricing strategies. Participants will learn what constitutes a strong price policy, how to leverage automation for price setting, and methods for predicting launch price corridors.

Featuring a revamped, more challenging bidding format for our interactive tender game, plus expanded content on negotiation and bidding theory.

Experience hands-on exercises with the latest AI features, master advanced prompt techniques for complex queries, and contribute to shaping our AI development roadmap.

A review of current policy changes, upcoming proposals, and insights on the future of healthcare policy under the Trump administration.

A deep dive into advanced IRP topics, their impact on pricing, and evolving rules. This session covers cutting-edge IRP techniques and hands-on exercises with NAVLIN IRP to tackle complex challenges, including:

• - Identifying informal rule behaviors
• - Portfolio forecasting
• - Developing a list price policy with IRP
• - Assessing in-line BD&L opportunities

Gain expert insights and practical skills to navigate the complexities of IRP effectively.

A review of key accomplishments over the past year, upcoming changes, product direction, and roadmap insights. Exclusive to NAVLIN customers.

Join us for cocktails and dinner at Portofino!

An update on NAVLIN, Global Value, Evidence, Price & Market Access environment to kickoff to our event.

Insights into our progress—what we’ve built, what’s in development, and how we’re making it happen. We’ll highlight key milestones, upcoming initiatives, and the strategies driving our success.

One of our special guest speakers, Carlos Moreira, Partner from PwC, will share his perspectives on global pricing.

A well-executed global Early Access Program (EAP) can accelerate revenue, expedite approvals, and enhance market access. However, missteps can create significant pricing and policy risks. This session will explore how to develop and implement a strategic EAP while effectively managing potential challenges to ensure long-term success.

In its second year, this enhanced survey provides deeper insights, refined metrics, and a more comprehensive view of pricing operations. Learn how to improve benchmarking accuracy and deliver greater value for strategic decision-making.

Learn how to efficiently create comprehensive product price and access landscapes while streamlining competitive tracking. This session will showcase strategies and tools to enhance speed, accuracy, and ease in monitoring market dynamics.

One of our distinguished guest speakers, Professor Schlander, from the Institute for Innovation & Valuation in Health Care, Professor of Health Economics at the University of Heidelberg, and Head of Health Economics at DKFZ German Cancer Research Center, will share his uniqe perspectives.

Join a dynamic roundtable featuring former payers and key industry influencers as they tackle your questions on access, reimbursement, and other critical topics in a fast-paced, open forum. Gain rapid insights across multiple markets in this unique opportunity for direct discussion. Space is limited—additional registration is required.

Smaller biotech launches, whether from a smaller organization or a narrowly targeted therapy at a large organization that does not get the same resources, is a critical aspect of launch. This session covers how to optimize smaller launches and what the implications are more broadly for the organization and how to communicate that efforts to all stakeholders

Join a dynamic roundtable featuring former payers and key industry influencers as they tackle your questions on access, reimbursement, and other critical topics in a fast-paced, open forum. Gain rapid insights across multiple markets in this unique opportunity for direct discussion. Space is limited—additional registration is required.

Effectively measuring and communicating price and market access success to senior executives, boards, and investors is more critical than ever. This session explores strategies for showcasing P&MA impact, the growing presence of these discussions in board meetings and investor calls, and how P&MA teams can proactively prepare themselves to meet the opportunity.

Join us for a discussion on assessing early asset valuation through a price and market access lens. We’ll explore the role of AI in predicting asset value, key considerations for early-stage evaluation, and strategies to drive informed decision-making.

Explore key tender pricing trends and learn how to analyze real-world tender data for deeper market insights. This session will showcase strategies for maximizing the value of NAVLIN Tender Data to drive smarter pricing and market access decisions.

Horizon scanning is essential for staying ahead of policy changes, access and reimbursement shifts, and competitive market dynamics. This session explores cutting-edge approaches to horizon scanning and how to leverage it for strategic decision-making.

Learn how to forecast, prepare for, and execute a successful strategy around loss of exclusivity. Whether defending the value of your asset or planning a biosimilar launch, this session will provide key insights and best practices to stay competitive.

Explore new ways to think about pricing and price policy during the launch phase. This session will provide fresh perspectives and strategies to optimize pricing decisions and maximize market success.

As companies seek to maximize margins and strategically position mature portfolios to support new product launches, pricing strategies are evolving. This session offers a comprehensive view of how to analyze and leverage mature product pricing to drive long-term value and competitive advantage.

Global Gross-to-Net forecasting is evolving, and pricing teams must ensure their approach aligns with finance, internal processes, and external policy changes. This session will focus on how to adapt forecasting strategies to avoid surprises and maintain accuracy across the organization.

Join us for a session on innovative ways to use IRP and NAVLIN IRP Express to address challenges beyond "mandatory price changes." Discover how these tools can enhance Business Development & Licensing (BD&L), competitor insights, and more to drive strategic decision-making.

Gene therapy now represents 10% of new approvals, with a growing pipeline and increasingly complex launches. This session will explore the future of gene therapy and provide insights on how Price & Market Access professionals can prepare as their companies enter gene therapy licensing deals for the first time.

Discover the all-new version of NAVLIN Mobile and how it’s designed to meet all your needs, directly from your mobile phone. Experience the convenience of accessing key tools and insights wherever you are, whenever you need them.

With new breakthroughs in CVRM and CNS, including Alzheimer's, creating opportunities in large population products and under-served areas, pricing and market access professionals face unique challenges. This session will explore strategies to navigate the renaissance in these broad therapy areas and address the impact on payer budgets and pricing.

From the upcoming U.S. election to evolving EU pharmaceutical legislation, ongoing changes in Japan, and mounting pressures in China, the pharmaceutical landscape is in flux. This session will explore what lies ahead during this time of significant policy uncertainty, offering expert insights and fearless forecasts on global pharmaceutical policy trends and their implications.

Join us for cocktails in the foyer following Closing Remarks!